Login +0086-27-65522453 [email protected]

Relugolix Catalog No : 16060701

Chemical Information

Product NameRelugolix
Iupac Chemical Name1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea 
SynonymsRelugolix; TAK385 
Molecular FormulaC29H27F2N7O5S 
Molecular Weight623.63 
SmileFC1=C(CN2C(N(C(C3=C2SC(=C3CN(C)C)C3=CC=C(C=C3)NC(=O)NOC)=O)C=3N=NC(=CC3)OC)=O)C(=CC=C1)F
InChiKeyAOMXMOCNKJTRQP-UHFFFAOYSA-N
InChiInChI=1S/C29H27F2N7O5S/c1-36(2)14-19-24-26(39)38(22-12-13-23(42-3)34-33-22)29(41)37(15-18-20(30)6-5-7-21(18)31)27(24)44-25(19)16-8-10-17(11-9-16)32-28(40)35-43-4/h5-13H,14-15H2,1-4H3,(H2,32,35,40)
Cas737789-87-6

Technical Data

AppearanceSolid powder 
Purity98% by HPLC 
SolubilitySoluble in DMSO 
Storage-20 ºC for 3 years 
Shipping ConditionShipped under ambient temperature 
Quality control

Description

 Relugolix, also known as TAK-385, is a luteinizing hormone-releasing hormone (LH-RH) receptor antagonist administered orally. By preventing LH-RH from binding with the LH-RH receptor in the anterior pituitary gland and suppressing the secretion of luteinizing hormone (LH) and follicle stimulation hormone (FSH) from the anterior pituitary gland, TAK-385 controls the effect of LH and FSH on the ovary, reduces the level of estrogen in blood, which is known to be associated with the development of endometriosis and uterine fibroids, and is expected to improve the symptoms of these disorders 

Chemical Structure

16060701 - Relugolix | CAS 737789-87-6

Package

SizePrice
Login to get price

Quick Order

Change

Contact Us